Epigenetics and Gut Microbiota in Children With Epilepsy — EpiMICRO  

Epilepsy Clinical Trial

Official title: The Potential Impact of the Ketogenic Diet on Epigenetics and Gut Microbiota in Children With Epilepsy

Status Recruiting

Clinical Trial Summary

The ketogenic diet is a high-fat, low-carbohydrate diet used in the treatment of epilepsy. The diet can be an efficient treatment option in children with drug resistant epilepsy, with more than 50 % seizure reduction in about 40- 70 % of the patients. However, there is still a lack of knowledge regarding the mechanisms of action, how will respond to the treatment and potential adverse effects.

Clinical Trial Description

The ketogenic diet is a high-fat, moderate protein, low-carbohydrate diet. It is an internationally established treatment option in children with drug resistant epilepsy. About 40 -70 % of children with drug resistant epilepsy treated with the ketogenic diet achieve > 50 % seizure reduction. However, even though the ketogenic diet has been used in the treatment of epilepsy for almost a Century, little is known about how the dietary treatment reduces seizures and which patients that will respond well. In addition, there is limited knowledge about potential adverse effects of the treatment. This is a prospective study following the patients from 4 weeks before initiating the ketogenic diet and during the treatment. The influence of the dietary treatment on the gut microbiota, epigenetics, quality of life, and adverse effects will be investigated. ;

Related Conditions & MeSH terms

• Epilepsy

• NCT number: NCT04063007
• Study type: Interventional
• Source: Oslo University Hospital
• Contact: Kaja K Selmer, PhD
• Phone: 0047 22 11 77 83
• Email: k.k.selmer@medisin.uio.no
• Status: Recruiting
• Phase: N/A
• Start date: August 15, 2017
• Completion date: November 1, 2022